# Nectar Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nectar-life-sciences

- Industry: Healthcare
- Headquarters: New York, US
- Website: www.mynectar.com
- Total disclosed funding: $32M
- Latest round: Series A (Nov 17, 2022)
- Investors on record: 3

## About

Founded in 2021 and based in New York, US, Nectar Life Sciences, Inc. operates as a healthcare platform that engages in determining possible allergies that could occur. Kenneth Chahine (CEO), Ben Oyler (COO), and Hersh Patel are the co-founders of the company. In November 2022, Nectar Life Sciences, Inc. raised USD 24.25 million in Series A funding from Harmony Partners, including Juxtapose and Obvious Ventures.

The company provides a vertically integrated platform for allergens that includes a hybrid virtual and physical clinic model, a compounding pharmacy, a lab testing facility, and a network of allergist physicians to create customer experiences and align incentives. The firm also provides custom-formulated under-the-tongue drops. Nectar tests for different types of allergens such as grasses, trees, weeds, pets, molds, dust mites, and others.

The startup generates revenue by selling indoor and outdoor allergy tests for USD 199 and monthly subscriptions to prescription allergy drops for USD 99.

The organization plans to use the November 2022 funding to invest in three key areas in 2023: scaling its virtual care platform nationwide, launching its first physical location to comprehensively treat allergies, and initiating clinical studies.

## Funding rounds

- Series A, Nov 17, 2022, $24M — Harmony Partners, Obvious, Juxtapose
- Seed, Mar 17, 2022, $8M — Obvious, Juxtapose

## Investors

- Obvious (https://capitalatlas.ai/funds/obvious) — Seed, Series A
- Juxtapose (https://capitalatlas.ai/funds/juxtapose) — Seed, Series A
- Harmony Partners (https://capitalatlas.ai/funds/harmony-partners) — Series A